Author Index, Volume 46 (2006)

Accomando J, 613
Adkison KK, 577
Agersø H, 1204
Agin M, 598
Ahmed T, 792
Alanis-Bañuelos RE, 527
Alcorn H Jr, 172
Almashhadani WM, 588
AlPachachi IA, 588
Al-Ramahi M, 925
Andonovski T, 468
Apseloff G, 1139
Aranda JV, 449, 508
Arnold ME, 1308
Arribas J, 265
Astuccio AV, 1426
Avula B, 214
Awada A, 1116
Azzaro AJ, 933
Bain MA, 1163
Bairaktari ET, 1337
Balakrishnan K, 1038
Barissa GR, 1328
Bastien M-C, 895
Bata MS, 925
Bauer R, 10
Bauman WA, 476
Becka M, 549, 981
Becker M, 1241
Bedikian AY, 727
Benda N, 867
Bennett DS, 1044
Bergman AJ, 291, 321, 328, 876
Berrey MM, 577
Bertino JS Jr, 103, 229, 345, 577
Bethke TD, 1146
Bies RR, 1052
Bifano M, 1250
Biswal S, 945
Blair EYL, 1370
Blob LF, 933
Blode H, 867
Blum RS, 394, 876
Boffito M, 130
Borgå O, 1417
Borland J, 577
Bosch JJ, 483
Bourbeau M, 758
Bouwer M, 768
Bradley-Alvarez F, 527
Bradstreet TE, 291
Bramson C, 29, 1030, 1212
Brandt J, 424
Brayshaw N, 235
Breen P, 201
Brennan BJ, 222
Brookman S, 461
Brophy DF, 887
Brown AB, 222
Brown NA, 275, 999
Bruce A, 214
Brun SC, 265
Burggraaf J, 483
Burke J, 321, 328
Burkhardt RT, 802
Burstein AH, 991, 1234, 1439
Butler K, 291
Butt K, 76
Butterweck V, 1390
Button J, 1379
Calcagni A Jr, 52, 693, 1030, 1212
Calis KA, 515
Calvo A, 1188, 1195
Cameron DW, 758
Campbell BJ, 933
Campbell P, 758
Campbell R, 613
Campbell S, 727
Cao C, 140
Carnahan RM, 1481
Carr ME Jr, 887
Carrier DJ, 201
Cater J, 1044
Causemaker SJK, 265
Cepeda C, 265
Chadha M, 1449
Chadik PA, 1449
Chalon S, 424
Chao GC, 275, 999
Chappell AS, 424
Chauhan BM, 758
Cheboyina S, 201
Chehab J, 508
Chen L, 876
Cheng A, 559
Chiang CN, 179
Choudhury MS, 1044
Chow MSS, 157
Chu V, 45
Chugani DC, 508
Chugani HT, 508
Chung M, 1030, 1212
Ciraulo AM, 179
Ciraulo DA, 179
Cirnigliaro CM, 476
Cisterni C, 715
Clark DJ, 991, 1234, 1439
Coats B, 1449
Cohen AF, 483
Coleman CI, 21
Compton P, 10
Constanzer M, 291
Cook J, 258
Court MH, 567, 1356
Coutant DE, 424
Cronin M, 867
Croop R, 1308
Crumley TM, 291
Culp KR, 1481
Cunningham F, 613
Cusic S, 1217
Daily JP, 1487
Damholt B, 635
Damle B, 1241
Damment SJP, 738
Daneshtalab N, 1344
Dang L, 662, 1259
Darpo B, 498, 598
DaSilva B, 265
Dasta JF, 968
Davies BE, 222
De Castro WV, 1390
de Kam ML, 483
De Lepeleire I, 291
De Porre P, 1116
de Queiróz Cunha F, 1328
De Smet PAGM, 1320
de Vries DE, 456
Dedrick R, 10
DeGroot T, 1139
Delaney MA, 1044
Demazières A, 715
Dennis K, 738
Derendorf H, 1390
Desai D, 301
Deutsch PJ, 1128
DeVane CL, 164
Di Spirito M, 785
Dilzer S, 876
DiMarco J, 895
DiMarco M, 642
Dirix LY, 1116
Dockens RC, 1308
Dogolo L, 693
Dokoumetzidis A, 1057
Donadi EA, 1328
Donovan JL, 164
dos Reis ML, 1328
Doyle JM, 401
Doyle R, 785
Dresser MJ, 301, 1023
Du W, 449
Du X, 69
Duffull S, 662, 1259
Dukic A, 468
Dunbar G, 715
Duncan B, 52
Dutta S, 952
Ebrahimi R, 559
Echizen H, 59
Edwards DJ, 508
Edwards KR, 17S
Ekblom M, 635
Elisaf M, 1337
Elizondo G, 527
El-Tahtawy A, 433
Eppler S, 282
Ereshefsky L, 424
Etminan M, 6
Evans AM, 1163
Faessel HM, 991, 1234, 1439
Fang L, 577
Fisher A, 1128
FitzGerald M, 6
Flores-Pérez C, 527
Flores-Pérez J, 527
Flynn JT, 905
Foss MC, 1328
Foster BC, 758
Fountaine RJ, 693
Fox L, 776
Francois M, 1116
Frattarelli DA, 1059
Freeman J, 1469
French DD, 613
Frentzen B, 1449
Frick A, 37, 45
Frick G, 321
Frohna P, 282
Frye RF, 1299
Fujita T, 674
Fukami T, 337
Fullerton T, 1234
Fulmor IE, 1308
Fumoleau P, 1116
Gandia P, 1008
Gao Y, 537
García Cabanillas JA, 265
Gardner MJ, 29, 52, 693
Garner RC, 456
Garovoy M, 10
Gartung AM, 103
Gazi I, 1337
Geerts H, 8S
Gefroh HA, 164
Gehr TWB, 887
Gelboin HV, 353
Gentry WB, 201
Gharaibeh MN, 925
Gibbs MA, 991, 1439
Gidwani S, 1023
Gill S, 6
Gillespie B, 1460
Glasser SP, 1106
Glue P, 1030, 1212
Gobey JS, 991
Goldberg MR, 291
Goldman P, 214
Goldstein JA, 515
Golor G, 635
Gooden C, 222
Goodisman J, 443
Goosen TC, 768
Gorostiaga C, 1195
Gottesdiener K, 321, 328, 917
Grabowski BA, 88

Grahnén A, 1417
Grasela DM, 193, 1250
Gray P, 598
Greenberg HE, 291, 321
Greenblatt DJ, 179, 214, 567, 1356, 1469
Grieve J, 1038
Grossberg GT, 8S, 17S
Guell A, 1008
Guharoy R, 850
Guilbaud R, 310
Guo C, 1023
Gupta S, 301, 1460
Gurley B, 201
Ha J-M, 109
Hadsall KZ, 802
Halldórsdóttir S, 1017
Hamilton M, 282
Hariharan S, 76
Harmatz JS, 214, 1469
Harnett M, 776
Hartmann S, 149
Harty L, 405
Hauns B, 1146
Hauschke D, 1146
He P, 1356
Henderson GN, 1449
Herman GA, 876
Hermann R, 1146
Herzog R, 1146
Hesney M, 1128
Hesse LM, 567
Hewlett D Jr, 1241
Hickey L, 291
Hilliard D, 876
Hinder M, 37, 45
Hinrichs JWJ, 1320
Hitzemann RJ, 179
Hoffer CJ, 1313
Holt DW, 1379
Hon YY, 408, 515
Horan KA, 214
Houin G, 1008
Howard G, 1106
Howard L, 291
Hsyu P-H, 1241
Hu P, 999
Huang J-D, 628
Hubbard MA, 201
Hünnemeyer A, 1146
Hunt TL, 895
Hustad CM, 172
Itoh M, 337
Jamali F, 1344
Jann MW, 408, 515
Jensen BK, 37, 45
Jhee SS, 424
Jia M, 1449
Jiang J, 999
Jiang X, 1370
Jilma B, 468
Johansson S, 1017
Johnson BM, 577
Johnson DW, 1259
Johnson K, 258, 405
Johnson-Levonas AO, 321, 328
Jorkasky DK, 598
Joseph-Ridge N, 88, 855
Joshi A, 10
Jovanovic D, 1217
June Tordoff J, 1038
Jusko WJ, 408, 515
Kahan BD, 76
Kaida S, 461
Kakkar T, 1460
Kalus JS, 21
Kambhampati SRP, 310
Kanamaluru V, 193
Kang D, 1023
Karim A, 140
Karlsson MO, 1204
Kastrissios H, 537
Kawabata K, 537
Kawai S, 418
Kays MB, 1154
Kazierad DJ, 598
Kearney BP, 559
Kearns G, 620
Kemper EM, 933
Kenkare-Mitra SR, 282
Kenyon SL, 1379
Khan IA, 214
Kharasch ED, 1313
Khosravan R, 88, 855
Kim E, 424
Kim K-A, 109
Kim M-J, 345
Kirby B, 1313
Kirshblum SC, 476
Kishi R, 59
Klem B, 456
Kling D, 785
Knapp CM, 179
Knops A, 291
Knorr B, 620
Kobayashi S, 59
Kokki H, 433
Kolis SJ, 222
Kootstra-Ros JE, 1320
Korth-Bradley JM, 418
Kosoglou T, 321, 328
Kostapanos MS, 1337
Kostara C, 1337
Kotey P, 917
Kothare PA, 1179
Kotzailias N, 468
Kovarik JM, 149, 895
Kowal P, 1299
Kraft WK, 321
Krausz K, 353
Krishna R, 966
Kubitza D, 549, 981
Kuchibhatla R, 715
Kuebler P, 10
Küfner A, 867
Kumagai Y, 674
Kuti JL, 69, 1171
Kwon P, 10
Laaksonen R, 812
LaCreta F, 1250
Lai M-L, 628
Lamba JK, 373
Lanchote VL, 1328
Lang NP, 802
Lappin G, 456
Laredo L, 1195
Lares-Asseff I, 527
Larson P, 321, 328
Lasseter K, 776, 876
LaValleur J, 1299
Layton G, 598
LeBlanc JM, 968
Leddy C, 10
Lee J, 310
Lee LS, 229
Lee S-J, 515
Legangneux E, 1469
Lehmann DF, 850
Lehtimäki T, 812
Le-Traon AP, 1008
Lewanczuk RZ, 1344
Li C, 69, 1171
Li J, 265
Li SX, 792
Li XD, 1290
Lin D, 301
Ling J, 282
Linnebjerg H, 1179
Liu F, 876
Liu H, 418
Liu J, 37
Liu S, 103
Lloyd DM, 275
Lockbaum P, 747
Lor M, 642
Lorenzo A, 265
Lou Y, 577
Lu J, 282
Lu W-L, 628
Luebbert JF, 1044
Lum BL, 282
Lum P, 747
Lund BC, 1481
Luo Y, 214
Lupinacci P, 792
Luthringer R, 715
Lütjohann D, 812
Ma JD, 103
Mace KF, 1179
Macheras P, 1057
Maganti L, 620
Mahan JD Jr, 905
Maitland D, 130
Majima M, 674
Majumdar AK, 291, 792, 1128
Malcolm RJ, 164
Malhotra S, 945
Malian M, 508
Malmstrom K, 917
Malone RP, 1044
Marier J-F, 310, 642
Marino MR, 193
Markowitz JS, 164
Martin EJ, 887
Martínez I, 1188
Maruyama S, 1290
Masuhara K, 59
Mathew P, 310
Mathew TH, 76
Matsumoto N, 59
Matsumoto Y, 674
Matsunaga T, 461
Matzke GR, 1299
Maxwell SE, 328
Mayer MD, 88
Mayersohn M, 398
McGratty M, 917
McKenney JM, 785
McKeown DA, 1379
McLachlan AJ, 1370
Meehan AG, 876
Meibohm B, 373
Mertens-Talcott SU, 1390
Metzger D, 715
Michiels N, 291
Migoya E, 620
Mihara K, 59
Milionis HJ, 1337
Milne RW, 1163
Milton A, 52
Mishra P, 945
Mistry GC, 1128
Mittan A, 559
Miyake F, 59
Moberly J, 310, 537
Modi NB, 301, 1023
Monreal A, 715
Moran SV, 424
Morelli G, 642
Moreno A, 1195
Morrison NG, 476
Mueck W, 549, 981
Muirhead G, 598
Mulhall JP, 1023
Murphy G, 321, 328
Murphy MG, 792
Nafziger AN, 103, 229, 345, 577
Nahata MC, 905
Nakajima M, 337
Nakazawa K, 59
Namdari R, 727
Narang VS, 1313
Natarajan G, 449
Nave R, 461
Nebout T, 498
Ni L, 654
Nicholson S, 456
Nicolau DP, 69, 1171
Nightingale CH, 69, 1171
Nilsson D, 1417
Nishizawa Y, 693
Nørgaard JP, 1204
Norris P, 1038
Obach RS, 1426
O'Connell MB, 1299
Ogawa R, 59
Ohashi K, 1290
Öhman KP, 1017
Ohmori Y, 1290
Ohtani Y, 674

Oki T, 1290
Olsen S, 1250
O'Mara EM, 193
Oosterhuis B, 456
Oren DA, 933
Østerberg O, 1204
Ouellet D, 29
Overholser BR, 1154
Ozaki M, 674
Ozoux M-L, 45
Paccaly A, 37, 45
Päivä H, 812
Pandhi P, 945
Panebianco D, 291, 792
Pantaleon C, 785
Paolini JF, 321, 328
Park J-Y, 109
Park P-W, 109
Park S, 1179
Paulauskis J, 258
Pedersen P, 635
Peloso PM, 654
Peng JZ, 265
Pennick M, 738
Pequignot E, 792
Perella P, 1379
Perez-Rodriguez J, 1449
Perkovic-Vukcevic N, 1217
Perloff ES, 214
Perry PJ, 1481
Petersen A, 1241
Petty KJ, 291, 792
Picard F, 149
Piccart-Gebhart M, 1116
Pietropaolo K, 999
Piscitelli SC, 577
Poggi JC, 1328
Pollock BG, 1481
Portman RJ, 905
Portolés A, 1188, 1195
Potvin D, 642
Power A, 405
Pozniak A, 130
Profy A, 776
Pruchnicki MC, 968
Pulido F, 265
Puri GD, 945
Rakhit A, 282
Ramakrishnan R, 620, 917
Ramanathan S, 559
Ramsey KE, 172
Rancic D, 1217
Randinitis E, 29
Reed RC, 952
Reicin A, 917
Reidenberg BE, 433
Reith D, 1038
Resplandy G, 1188, 1195
Reyderman L, 321, 328
Reynolds RC, 214
Rheeders M, 768
Rhodes G, 103
Rice K, 1469
Riviere G-J, 149
Robson R, 328, 1460
Rodgers A, 172
Rohatagi S, 37, 537
Rohrbacher K, 1439
Roman D, 29
Rosen L, 792
Rosenburg R, 37, 45
Rosenthal M, 424
Roskos LK, 747
Rothenberg PL, 291
Rotrosen J, 179
Royalty JE, 792
Rubenstein LZ, 613
Rushmore TH, 792
Russell AS, 1344
Rutman O, 222
Sabounjian L, 776
Sædder EA, 642
Sager PT, 498
Saieed WN, 588
Saivin S, 1008
Salaita CG, 515
Salari V, 449
Salazar DE, 310, 537, 1308
Salfi M, 654, 1460
Salhab AS, 925
Samii A, 6
Samuelsson S, 1017
Sandage B, 776
Sarid-Segal O, 179
Savic RM, 1204
Scharre DW, 6S
Schentag JJ, 968
Schmidt HH-J, 149
Schmouder RL, 149, 895
Schuetz E, 373
Schürmann R, 867
Schwab G, 747
Schwartz J, 925
Seguin I, 758
Sekino H, 418
Sellers EM, 345
Serebruany VL, 468
Serra D, 895
Shah A, 1139
Shalwitz RA, 785
Sharoky M, 933
Sheelo C, 654
Shipley J, 776
Shukla N, 373
Shukla U, 37, 45
Sica D, 1128
Simon M, 301
Simonsson USH, 1204
Skobieranda F, 172
Smith B, 1460
Smith BJ, 991
Smith RA, 193, 1250
Smith T, 727
Snyder K, 876
Somoza E, 179
Song IH, 577
Song P, 373
Soon D, 1179
Sosa-Macías M, 527
Souid A-K, 443
Sowinski KM, 1154
Spehar A, 613
Spratlin VE, 408, 515
Spungen AM, 476
Srnic D, 1217
St. Peter JV, 1299
Stacpoole PW, 1449
Staehr P, 1023
Statkevich P, 321, 328
Stenhoff H, 1017
Stevens C, 876
Stolar M, 1439
Stork CM, 850
Straka RJ, 802
Strid S, 1417
Sullivan JT, 654, 1460
Swan S, 1128
Swan SK, 172
Swearingen D, 785
Takagi A, 59
Takahashi H, 59
Takahashi M, 537
Tan K, 235
Tanaka W, 876
Tanen M, 876
Tang H, 398
Taylor A, 52
Teigen MMB, 1259
Terleira A, 1188, 1195
Thaden J, 201
Thelen KM, 812
Thummel KT, 1313
Tokudome S, 337
Tolbert D, 140
Tomaszewski K, 235
Tomlinson B, 157
Tong Y, 201
Toublanc N, 424
Tozzi CA, 620
Troke P, 235
Truitt K, 537
Tsai MY, 802
Tsuchiwata S, 418
Twiss IM, 483
Uchida S, 1290
Umegaki K, 1290
Unadkat JD, 1313
Van Buren C, 76
van de Wetering J, 456
van den Berk AHM, 483
van der Weide J, 1320
van Heeswijk RPG, 758
Van Weelden MJM, 1320
VanDenBerg CM, 933
Vardeleon A, 727
Venitz J, 887
Verhaeghe T, 1116
Vermeij P, 483
Vernillet L, 88, 855
von Moltke LL, 214, 567, 714, 1356
Voss B, 149
Wada R, 537
Wagner F, 149
Wagner JA, 876, 917, 1128
Waldman SA, 291
Walicke P, 10
Walle JV, 1204
Walsky RL, 1426
Wang AQ, 876
Wang H, 999
Wang J, 1460
Wang J-S, 164
Wang Y, 895
Warrier I, 449
Watanabe H, 1290
Wehling M, 1308
Wei G, 52, 693
Weinling E, 1469
Weiss M, 149
Welch MR, 1299
Wemer J, 1417
White CM, 21
White M, 10
Wierich W, 635
Willhite LA, 1299
Williams DK, 201
Williams JA, 258
Wingertzahn MA, 461
Wise SD, 1179
Wolf J, 282
Woll S, 172
Wood N, 235
Wu J-T, 88, 855
Xi L, 1128
Xu Y, 1128
Yamada H, 1290
Yamada S, 1290
Yamamoto H, 337
Yamamoto Y, 337
Yamanaka H, 337
Yamashita N, 418
Yan J-H, 193, 1250
Yang B-B, 747
Yates CR, 373
Yin OQP, 157
Yokoi T, 337
Yost RA, 1449
Yuen E, 1179
Zadezensky I, 1390
Zammit GK, 1469
Zannikos P, 1116
Zarotsky V, 424
Zdravkovic M, 635
Zech K, 1146
Zeng W, 876
Zhang D, 1250
Zhang L, 373
Zhang R-L, 476
Zhang S, 1116
Zhang X, 1154
Zhang Y, 345
Zhao Q, 17S
Zhou H, 1268
Zhou X-J, 275, 999
Zhu H-J, 164
Zia-Amirhosseini P, 1460
Zimmerman JJ, 76
Zuehlsdorf M, 549, 981

Subject Index, Volume 46 (2006)

γ-aminobutyric acid
effect of low-dose baclofen administration on plasma insulin-like growth factor-I in persons with spinal cord injury, 476

1-PP
pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range, 1308

24S-hydroxycholesterol
high-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels, 812

27-hydroxycholesterol
high-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels, 812

5-HT_3 Receptor antagonists
pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects, 1139

6-hydroxybuspirone
pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range, 1308

6-hydroxychlorzoxazone
effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe, 109

8-methoxypsoralen
drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine, 768

Accelerator mass spectrometry
determination of the bioavailability of [^{14}C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers, 456

Acute ischemic stroke
NXY-059 does not significantly interact with furosemide in healthy volunteers, 1417

Adrenal function
safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis, 461

Adverse events
investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities, 235

Age
pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: impact of age and effects of a high-fat meal, 1023

Albumin
rosuvastatin increases a-1 microglobulin urinary excretion in patients with primary dyslipidemia, 1337

Allele frequency
CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico, 527

Alpha-1 microglobulin
rosuvastatin increases a-1 microglobulin urinary excretion in patients with primary dyslipidemia, 1337

Alzheimer's disease
pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers, 715
pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease, 8S
rationale for combination therapy with galantamine and memantine in Alzheimer's disease, 17S

Aminoglycosides
dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis, 1259

Amlodipine
population pharmacokinetics of amlodipine in hypertensive children and adolescents, 905

Amlodipine besylate
bioavailability of amlodipine besylate/atorvastatin calcium combination tablet, 1030

AMPA receptor potentiators
multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects, 424

Angiotensin II type 1 receptor
drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis, 1344

Angiotensin receptor antagonist
impact of suppressing the renin-angiotensin system on atrial fibrillation, 21

Angiotensin-converting enzyme inhibitors (ACE)
impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors, 968
impact of suppressing the renin-angiotensin system on atrial fibrillation, 21

Antacid
effect of food, an antacid, and the H_2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects, 549

Anti-CD11a
overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis, 10

Anticholinergics
anticholinergic drug scale as a measure of drug-related anticholinergic burden, 1481

Anticoagulants
investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach, 1370
pharmacokinetic/pharmacodynamic relationships for Otamixaban, a direct factor Xa inhibitor, in healthy subjects, 45

Antidepressants
therapeutic drug monitoring of antidepressants and cytochrome P450 genotyping in general practice, 1320

Antifactor Xa activity
pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies, 887

Antimalarial therapy
antimalarial drug therapy: the role of parasite biology and drug resistance, 1487

Antithrombotic agents
pharmacokinetic/pharmacodynamic relationships for Otamixaban, a direct factor Xa inhibitor, in healthy subjects, 45

Antiviral
absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects, 275

Anxiety
pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range, 1308

Aprepitant
lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers, 792
pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers, 291

Area under the time-concentration curve (AUC)
comparison of maximum drug concentration and area under the time-concentration curve between humans and animals for oral and intravenous investigational drugs, 674

Arthritis
bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections, 654

comparability of etanercept pharmacokinetics in healthy Japanese and American subjects, 418

Aspirin

antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial, 468
effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe, 109
safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin, 981

AST-120

effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects, 310

Atorvastatin calcium

bioavailability of amlodipine besylate/atorvastatin calcium combination tablet, 1030

Atrial fibrillation

impact of suppressing the renin-angiotensin system on atrial fibrillation, 21

Autism

pharmacokinetics of buspirone in autistic children, 508

BAY 59-7939

effect of food, an antacid, and the H_2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects, 549
safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin, 981

Bed rest

influence of simulated weightlessness on the intramuscular and oral pharmacokinetics of promethazine in 12 human volunteers, 1008

Bioavailability

absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate, 738
determination of the bioavailability of [^{14}C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers, 456
evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects, 282
pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers, 291
safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis, 461

Bioequivalence

bioavailability of amlodipine besylate/atorvastatin calcium combination tablet, 1030
bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections, 654
evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects, 282

Biomarker

evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified Cooperstown 5 + 1 cocktail, 577

Bladder cancer

determination of the bioavailability of [^{14}C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers, 456

Body surface area normalization

comparison of maximum drug concentration and area under the time-concentration curve between humans and animals for oral and intravenous investigational drugs, 674

Botanical supplements

assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin, 201

Brain cholesterol

high-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels, 812

Bronchiolitis

pharmacokinetics and safety of montelukast in children aged 3 to 6 months, 620

Brugada syndrome

population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias, 59

Buspirone

pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range, 1308
pharmacokinetics of buspirone in autistic children, 508

Caffeine

discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects, 802
effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women, 1299

Cancer

determination of the bioavailability of [^{14}C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers, 456
pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer, 1116

Carboplatin

constancy in integrated cisplatin plasma concentrations among pediatric patients, 443

Cardiac rate and rhythm

FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects, 895

Case control studies

challenges and opportunities for pharmacoepidemiology in drug-therapy decision making, 6

CCR5

evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified Cooperstown 5 + 1 cocktail, 577

Cerebrospinal fluid

multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects, 424

Chlorzoxazone

effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women, 1299
effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe, 109

Chronic kidney disease

effect of renal function on the pharmacokinetics of palifermin, 1460

Cisplatin

constancy in integrated cisplatin plasma concentrations among pediatric patients, 443

Clinical pharmacology

clinical pharmacology of the appeals and exception process: the interface of the patient, physician, and insurance company to assure appropriate care under Medicare Part D, 394

Clinical relevance

grapefruit-drug interactions, 1390

Clinical studies

anticholinergic drug scale as a measure of drug-related anticholinergic burden, 1481
antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial, 468
delay of ovulation by meloxicam in healthy cycling volunteers: a placebo-controlled, double-blind, crossover study, 925
dental impaction pain model as a potential tool to evaluate drugs with efficacy in neuropathic pain, 917
drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis, 1344
effect of low-dose baclofen administration on plasma insulin-like growth factor-I in persons with spinal cord injury, 476
high-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels, 812
impact of suppressing the renin-angiotensin system on atrial fibrillation, 21
lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial, 1195

multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects, 424
pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus, 1328
pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects, 172
pharmacokinetics and safety of montelukast in children aged 3 to 6 months, 620
predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin, 776
rosuvastatin increases a-1 microglobulin urinary excretion in patients with primary dyslipidemia, 1337
safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis, 461
therapeutic drug monitoring of antidepressants and cytochrome P450 genotyping in general practice, 1320
what race and ethnicity measure in pharmacologic research, 401

Clinical trials

effects of *Hypericum perforatum* on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial, 1188
at least 10 things you should look for in clinical trials, 1106

Cohort studies

challenges and opportunities for pharmacoepidemiology in drug-therapy decision making, 6

Combination tablet

bioavailability of amlodipine besylate/atorvastatin calcium combination tablet, 1030

Combination therapy

rationale for combination therapy with galantamine and memantine in Alzheimer's disease, 17S

Comorbidity

national Veterans Health Administration hospitalizations for syncope compared to acute myocardial infarction, fracture, or pneumonia in community-dwelling elders: outpatient medication and comorbidity profiles, 613

Corticosteroids

altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism, 408

Cortisol

altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism, 408
safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis, 461

Coumarin

isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6, 337

COX-2 inhibitors

development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor, 537

C-reactive protein

drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis, 1344

Cyclosporine

drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine, 768
effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects, 321
interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients, 328

CYP2A6

isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6, 337

CYP2C9

effects of ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers, 1290

CYP2D6

CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico, 527
lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers, 792

CYP3A

effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe, 103
human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity, 1356
simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities, 1313
use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults, 345

CYP3A4

effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men, 222
effects of ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers, 1290
lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers, 792

CYP3A5*3 allele

reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition, 515

Cytochrome P450

assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin, 201
effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women, 1299
effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe, 103
evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified Cooperstown 5 + 1 cocktail, 577
isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6, 337
limited sampling models for oral midazolam, 229
monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm, 353
therapeutic drug monitoring of antidepressants and cytochrome P450 genotyping in general practice, 1320

Cytochrome P450 2B6

evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6, 1426

Cytochrome P450 2E1 (CYP2E1)

effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe, 109

Cytochrome P450-2C9

ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate, 214

Dapoxetine

pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: impact of age and effects of a high-fat meal, 1023
single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation, 301

Dapsone

effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women, 1299

Dental impaction pain

dental impaction pain model as a potential tool to evaluate drugs with efficacy in neuropathic pain, 917

Depression

impersistence of depression in youth: implications for drug study design, 1044
tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects, 933

Desmopressin

pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults, 1204

Dextromethorphan

effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women, 1299

Diabetes

food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, 1017

open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide, 635

pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus, 1328

Dialysis

pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies, 887

Dichloroacetate

human kinetics of orally and intravenously administered low-dose 1,2-^{13}C-dichloroacetate, 1449

Digoxin

predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin, 776

simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities, 1313

Direct factor Xa inhibitor

effect of food, an antacid, and the H_2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects, 549

Disinfection by-products

human kinetics of orally and intravenously administered low-dose 1,2-^{13}C-dichloroacetate, 1449

Dolasetron

lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers, 792

Donepezil

rationale for combination therapy with galantamine and memantine in Alzheimer's disease, 17S

Dose adjustment

fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function, 149

DPP-4

pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects, 876

Drospirenone

effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function, 867

Drug delivery

pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients, 727

Drug discovery

monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm, 353

Drug disposition

establishing functional relevance of genetic polymorphisms on pharmacokinetics, 258

Drug interactions

absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects, 559

assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin, 201

drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine, 768

effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects, 310

effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women, 1299

effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men, 1179

effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe, 109

effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers, 193

effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine, 628

effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects, 321

effects of ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers, 1290

effects of *Hypericum perforatum* on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial, 1188

evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6, 1426

evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified Cooperstown 5 + 1 cocktail, 577

ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate, 214

grapefruit-drug interactions, 1390

interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients, 328

lack of effect of aprepitant on hydrodolasetron pharmacokinetics in CYP2D6 extensive and poor metabolizers, 792

lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial, 1195

NXY-059 does not significantly interact with furosemide in healthy volunteers, 1417

pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs, 855

population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures? 1268

practical perspectives on the use of tipranavir in combination with other medications, 130

predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin, 776

ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers, 567

study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters, 785

time-dependent interaction between lopinavir/ritonavir and fexofenadine, 758

Drug metabolism

assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin, 201

effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women, 1299

effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe, 103

effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men, 222

evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6, 1426

ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate, 214

isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6, 337

limited sampling models for oral midazolam, 229

monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm, 353

pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range, 1308

use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults, 345

Drug-metabolizing enzymes

establishing functional relevance of genetic polymorphisms on pharmacokinetics, 258

Drug modeling

constancy in integrated cisplatin plasma concentrations among pediatric patients, 443

Drug resistance

antimalarial drug therapy: the role of parasite biology and drug resistance, 1487

Drug safety

challenges and opportunities for pharmacoepidemiology in drug-therapy decision making, 6

national Veterans Health Administration hospitalizations for syncope compared to acute myocardial infarction, fracture, or pneumonia in community-dwelling elders: outpatient medication and comorbidity profiles, 613

tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects, 933

Drug transporters

establishing functional relevance of genetic polymorphisms on pharmacokinetics, 258

Drug utilization

in the intensive care unit of a tertiary care hospital, 945

patterns of drug utilization in a neonatal intensive care unit, 449

ECG methodology

clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs, 498

man versus machine: is there an optimal method for QT measurements in thorough QT studies? 598

Efalizumab

overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis, 10

Efficacy failure

comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection, 76

Elderly

impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors, 968

pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers, 1234

Electroencephalography

dynamics and kinetics of a modified-release formulation of zolpidem, 1469

Emphysema

effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men, 222

Enantiomers

pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus, 1328

Endogenous steroid hormones

use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults, 345

End-stage renal disease

dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis, 1259

Enoxaparin

pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies, 887

Entecavir

entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects, 1250

Environmental toxicology

human kinetics of orally and intravenously administered low-dose 1,2-^{13}C-dichloroacetate, 1449

Ergoloid mesylates

effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine, 628

Erlotinib

evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects, 282

Ertapenem

pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis, 1128

Estrogen

effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women, 1299

Etanercept

bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections, 654

comparability of etanercept pharmacokinetics in healthy Japanese and American subjects, 418

Ethnicity

CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico, 527

race and ethnicity in the era of emerging pharmacogenomics, 405

what race and ethnicity measure in pharmacologic research, 401

Evening dosing

single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers, 991

Exenatide

effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men, 1179

Ezetimibe

effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects, 321

interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients, 328

Factor Xa inhibitors

safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin, 981

FDA

what race and ethnicity measure in pharmacologic research, 401

Febuxostat

effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, 88

pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs, 855

Fenoprofen

pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus, 1328

Fentanyl

pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects, 642

Fexofenadine

time-dependent interaction between lopinavir/ritonavir and fexofenadine, 758

Fingolimod

fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function, 149

Fluorescence cystoscopy

determination of the bioavailability of [^{14}C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers, 456

Flurbiprofen kinetics

ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate, 214

Follicle rupture

delay of ovulation by meloxicam in healthy cycling volunteers: a placebo-controlled, double-blind, crossover study, 925

Food effects

absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects, 275

effect of food, an antacid, and the H_2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects, 549

food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, 1017

investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects, 1146

pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers, 291

pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: impact of age and effects of a high-fat meal, 1023

single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers, 991

Formulary

clinical pharmacology of the appeals and exception process: the interface of the patient, physician, and insurance company to assure appropriate care under Medicare Part D, 394

FTY720

placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects, 895

Furanocoumarin

drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine, 768

Furosemide

NXY-059 does not significantly interact with furosemide in healthy volunteers, 1417

FXa inhibitor
pharmacokinetics of Otamixaban, a direct factor Xa inhibitor, in healthy male subjects, 37

Galantamine
pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease, 8S
rationale for combination therapy with galantamine and memantine in Alzheimer's disease, 17S

Gas chromatography
disposition and metabolite kinetics of oral L-carnitine in humans, 1163

Gatifloxacin
gatifloxacin pharmacokinetics in healthy men and women, 1154

G-CSF
pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects, 747

Gender
gatifloxacin pharmacokinetics in healthy men and women, 1154
pharmacokinetics of buspirone in autistic children, 508

Genetics
race and ethnicity in the era of emerging pharmacogenomics, 405
therapeutic drug monitoring of antidepressants and cytochrome P450 genotyping in general practice, 1320
variability in renal clearance of substrates for renal transporters in Chinese subjects, 157
what race and ethnicity measure in pharmacologic research, 401

Genotyping
development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor, 537
discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects, 802
reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition, 515

Gentamicin
development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis, 662

Ginkgo biloba
effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine, 628
effects of ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers, 1290
ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate, 214
investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach, 1370

Glucagon-like peptide-1 analogue
open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide, 635

Glycemic efficacy
pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects, 876

Grapefruit
grapefruit-drug interactions, 1390

Growth hormone
effect of low-dose baclofen administration on plasma insulin-like growth factor-I in persons with spinal cord injury, 476

Hemodialysis
development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis, 662
dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis, 1259

Hepatic impairment
effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, 88
fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function, 149
impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors, 968
pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment, 265
pharmacokinetics of nelfinavir in subjects with hepatic impairment, 1241
single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment, 29

Hepatitis B
absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects, 275
single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects, 999

Herbal products
ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate, 214
investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach, 1370

Hexaminolevulinate (HAL)
determination of the bioavailability of [^{14}C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers, 456

Hexvix
determination of the bioavailability of [^{14}C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers, 456

High-affinity melatonin MT1/MT2 receptor
disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia, 140

Histamine suppression
altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism, 408

HIV/HCV
absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects, 559
pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment, 265
time-dependent interaction between lopinavir/ritonavir and fexofenadine, 758

HNMT polymorphism
altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism, 408

Hospital pharmacology
alternative model for practice and training in clinical pharmacology, 850

Hospitalization
national Veterans Health Administration hospitalizations for syncope compared to acute myocardial infarction, fracture, or pneumonia in community-dwelling elders: outpatient medication and comorbidity profiles, 613

HPLC/MS/MS
evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6, 1426

Human clearance
on the observed large interspecies overprediction of human clearance ("vertical allometry") of UCN-01: further support for a proposed model based on plasma protein binding, 398

Human pregnane X receptor (hPXR)
human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity, 1356

Hypericum perforatum
effects of *Hypericum perforatum* on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial, 1188

Hyperkalemia
effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function, 867

Hyperlipidemia
study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters, 785

Hypertension
population pharmacokinetics of amlodipine in hypertensive children and adolescents, 905

Hypertriglyceridemia
study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters, 785

ICH E14
clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs, 498

ICU
drug utilization pattern in the intensive care unit of a tertiary care hospital, 945

Immunomodulators
FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects, 895

Immunosuppression
fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function, 149

Immunotherapy
comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection, 76

In vitro
evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6, 1426

Incretins
pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects, 876

Indomethacin
pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs, 855

Inflammation
drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis, 1344

Insomnia
disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia, 140

Intranasal corticosteroid
safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis, 461

Isoflavones
isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6, 337

Ispronicline
pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers, 715

Ivabradine
lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial, 1195

Keratinocyte growth factor
effect of renal function on the pharmacokinetics of palifermin, 1469

Kidney disease
effect of renal function on the pharmacokinetics of palifermin, 1469

Lansoprazole
lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial, 1195

Lanthanum
absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate, 738

Lasofoxifene
clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women, 52
single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment, 29

Lathosterol
high-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels, 812

L-carnitine
disposition and metabolite kinetics of oral L-carnitine in humans, 1163

Lidocaine
dental impaction pain model as a potential tool to evaluate drugs with efficacy in neuropathic pain, 917

Linear regression analysis
comparison of maximum drug concentration and area under the time-concentration curve between humans and animals for oral and intravenous investigational drugs, 674

Liposomes
pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients, 727

Liraglutide
open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide, 635

Liver function test
investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities, 235

Lopinavir/ritonavir
pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment, 265
time-dependent interaction between lopinavir/ritonavir and fexofenadine, 758

Losartan
effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects, 310

Low-carbohydrate diet
reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition, 515

Low–molecular weight heparin
pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies, 887

M8
pharmacokinetics of nelfinavir in subjects with hepatic impairment, 1241

Matrix transdermal delivery system
pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects, 642

Maximum drug concentration (C_{max})
comparison of maximum drug concentration and area under the time-concentration curve between humans and animals for oral and intravenous investigational drugs, 674

Medicare Part D
clinical pharmacology of the appeals and exception process: the interface of the patient, physician, and insurance company to assure appropriate care under Medicare Part D, 394

Meloxicam
delay of ovulation by meloxicam in healthy cycling volunteers: a placebo-controlled, double-blind, crossover study, 925

Memantine
pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease, 8S
rationale for combination therapy with galantamine and memantine in Alzheimer's disease, 17S

Meningitis
population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients, 69

Mephenytion
effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women, 1299

Meropenem
population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients, 1171
population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients, 69

Methods
determination of the bioavailability of [^{14}C]-hexaminolevulinate using accelerator mass spectrometry after intravesical administration to human volunteers, 456
man versus machine: is there an optimal method for QT measurements in thorough QT studies? 598

Methoxsalen
drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine, 768

Methylprednisolone clearance
reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition, 515

Methylprednisolone pharmacodynamics
altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism, 408

Midazolam
effect of R667, a novel emphysema agent, on the pharmacokinetics of midazolam in healthy men, 222
limited sampling models for oral midazolam, 229
simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities, 1313

Migraine medication
pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects, 172

MK-0431
pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects, 876

Modified release
dynamics and kinetics of a modified-release formulation of zolpidem, 1469

Monoamine oxidase inhibitor
tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects, 933

Monoclonal antibodies
monoclonal antibodies and multifunctional cytochrome P450: drug metabolism as paradigm, 353

Mucositis
effect of renal function on the pharmacokinetics of palifermin, 1460

Multiple dosing
multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers, 1439

N-acetyltransferase 2
discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects, 802

Naloxone
pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials, 179

Naproxen
pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs, 855

Nasal allergies
safety, tolerability, and exposure of ciclesonide nasal spray in healthy and asymptomatic subjects with seasonal allergic rhinitis, 461

Nelfinavir
effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers, 193
pharmacokinetics of nelfinavir in subjects with hepatic impairment, 1241

Neonatal intensive care unit
patterns of drug utilization in a neonatal intensive care unit, 449

Neuropathic pain
dental impaction pain model as a potential tool to evaluate drugs with efficacy in neuropathic pain, 917

Neuroprotectant
NXY-059 does not significantly interact with furosemide in healthy volunteers, 1417

New medical entities
pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002, 1038

Nicotine acetylcholine receptor (nAChR)
pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers, 715

Nicotine metabolism
isoflavones inhibit nicotine C-oxidation catalyzed by human CYP2A6, 337

Nicotinic receptors
pharmacology of acetylcholinesterase inhibitors and N-methyl-D-aspartate receptors for combination therapy in the treatment of Alzheimer's disease, 8S

NN2211
open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide, 635

N-nitrosodimethylamine
disposition and metabolite kinetics of oral L-carnitine in humans, 1163

Nonlinear kinetics
pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects, 747

Nonlinear mixed-effect modeling
population-based assessments of clinical drug-drug interactions: qualitative indices or quantitative measures? 1268

NSAID
pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs, 855

NXY-059
NXY-059 does not significantly interact with furosemide in healthy volunteers, 1417

Obesity
pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects, 876

Off-label
pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002, 1038

Olanzapine
pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers, 164

Omega-3-acid ethyl esters
study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters, 785

Omeprazole
lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial, 1195
use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults, 345

Opioids
pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials, 179
population pharmacokinetics of oxycodone in children 6 months to 7 years old, 433

Oral adsorbent
effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects, 310

Oral anticoagulants
safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin, 981

Orally disintegrating tablets
pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects, 172
pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers, 164

Osteoporosis
clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women, 52
single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment, 29

Otamixaban
pharmacokinetic/pharmacodynamic relationships for Otamixaban, a direct factor Xa inhibitor, in healthy subjects, 45
pharmacokinetics of Otamixaban, a direct factor Xa inhibitor, in healthy male subjects, 37

Pain model
dental impaction pain model as a potential tool to evaluate drugs with efficacy in neuropathic pain, 917

Palifermin
effect of renal function on the pharmacokinetics of palifermin, 1460

Palonosetron
pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects, 1139

Paraplegia
effect of low-dose baclofen administration on plasma insulin-like growth factor-I in persons with spinal cord injury, 476

Partial agonist
pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials, 179

Patients' rights
clinical pharmacology of the appeals and exception process: the interface of the patient, physician, and insurance company

to assure appropriate care under Medicare Part D, 394

Pediatrics

constancy in integrated cisplatin plasma concentrations among pediatric patients, 443
impersistence of depression in youth: implications for drug study design, 1044
patterns of drug utilization in a neonatal intensive care unit, 449
pediatric licensing status and the availability of suitable formulations for new medical entities approved in the United States between 1998 and 2002, 1038
pharmacokinetics and safety of montelukast in children aged 3 to 6 months, 620
pharmacokinetics of buspirone in autistic children, 508
population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients, 69
population pharmacokinetics of amlodipine in hypertensive children and adolescents, 905
population pharmacokinetics of oxycodone in children 6 months to 7 years old, 433

Pegfilgrastim

pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects, 747

Peroxisome proliferator-activated receptor (PPAR)

food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, 1017

Personalized medicine

clinical pharmacology of the appeals and exception process: the interface of the patient, physician, and insurance company to assure appropriate care under Medicare Part D, 394

P-glycoprotein

time-dependent interaction between lopinavir/ritonavir and fexofenadine, 758

P-gp

simultaneous measurement of in vivo P-glycoprotein and cytochrome P450 3A activities, 1313

Pharmacoepidemiology

challenges and opportunities for pharmacoepidemiology in drug-therapy decision making, 6
drug utilization pattern in the intensive care unit of a tertiary care hospital, 945

Pharmacogenetics

altered methylprednisolone pharmacodynamics in healthy subjects with histamine N-methyltransferase C314T genetic polymorphism, 408
establishing functional relevance of genetic polymorphisms on pharmacokinetics, 258

Pharmacogenomics

CYP2D6 genotype and phenotype in Amerindians of Tepehuano origin and Mestizos of Durango, Mexico, 527
discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects, 802
human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity, 1356
race and ethnicity in the era of emerging pharmacogenomics, 405
reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition, 515

Pharmacokinetics and pharmacodynamics

absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects, 559
absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects, 275
absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate, 738
assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin, 201
bioavailability of amlodipine besylate/atorvastatin calcium combination tablet, 1030
bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections, 654
clinical pharmacology of multiple doses of lasofoxifene in postmenopausal women, 52
comparability of etanercept pharmacokinetics in healthy Japanese and American subjects, 418
comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection, 76
comparison of maximum drug concentration and area under the time-concentration curve between humans and animals for oral and intravenous investigational drugs, 674
constancy in integrated cisplatin plasma concentrations among pediatric patients, 443
development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor, 537
development of a semimechanistic model to describe the pharmacokinetics of gentamicin in patients receiving hemodialysis, 662
disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia, 140
dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis, 1259
dynamics and kinetics of a modified-release formulation of zolpidem, 1469
effect of AST-120 on the single-dose pharmacokinetics of losartan and losartan acid (E-3174) in healthy subjects, 310
effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function, 867
effect of food, an antacid, and the H_2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects, 549
effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, 88
effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers, 193
effect of renal function on the pharmacokinetics of palifermin, 1460
effects of ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers, 1290
effects of *Hypericum perforatum* on ivabradine pharmacokinetics in healthy volunteers: an open-label, pharmacokinetic interaction clinical trial, 1188
entecavir pharmacokinetics, safety, and tolerability after multiple ascending doses in healthy subjects, 1250
establishing functional relevance of genetic polymorphisms on pharmacokinetics, 258
evaluation of the absolute oral bioavailability and bioequivalence of erlotinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in a randomized, crossover study in healthy subjects, 282
fingolimod (FTY720) in severe hepatic impairment: pharmacokinetics and relationship to markers of liver function, 149
food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, 1017
FTY720: placebo-controlled study of the effect on cardiac rate and rhythm in healthy subjects, 895
gatifloxacin pharmacokinetics in healthy men and women, 1154
human kinetics of orally and intravenously administered low-dose 1,2-^{13}C-dichloroacetate, 1449
impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors, 968
influence of simulated weightlessness on the intramuscular and oral pharmacokinetics of promethazine in 12 human volunteers, 1008
investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects, 1146
investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach, 1370
lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial, 1195
limited sampling models for oral midazolam, 229
multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers, 1439
multiple-dose plasma pharmacokinetic and safety study of LY450108 and LY451395 (AMPA receptor potentiators) and their concentration in cerebrospinal fluid in healthy human subjects, 424
NXY-059 does not significantly interact with furosemide in healthy volunteers, 1417
open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide, 635

overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis, 10
pharmacodynamics, chiral pharmacokinetics, and pharmacokinetic-pharmacodynamic modeling of fenoprofen in patients with diabetes mellitus, 1328
pharmacokinetic evaluation and safety profile of a 15-minute versus 30-second infusion of palonosetron in healthy subjects, 1139
pharmacokinetic interactions of concomitant administration of febuxostat and NSAIDs, 855
pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects, 172
pharmacokinetic/pharmacodynamic modeling of pegfilgrastim in healthy subjects, 747
pharmacokinetic/pharmacodynamic relationships for Otamixaban, a direct factor Xa inhibitor, in healthy subjects, 45
pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers, 1234
pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects, 642
pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects, 876
pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials, 179
pharmacokinetics and safety profile of ispronicline (TC-1734), a new brain nicotinic receptor partial agonist, in young healthy male volunteers, 715
pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients, 727
pharmacokinetics of a newly identified active metabolite of buspirone after administration of buspirone over its therapeutic dose range, 1308
pharmacokinetics of aprepitant after single and multiple oral doses in healthy volunteers, 291
pharmacokinetics of buspirone in autistic children, 508
pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: impact of age and effects of a high-fat meal, 1023
pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults, 1204
pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies, 887
pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis, 1128
pharmacokinetics of lopinavir/ritonavir in HIV/hepatitis C virus-coinfected subjects with hepatic impairment, 265
pharmacokinetics of nelfinavir in subjects with hepatic impairment, 1241
pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers, 164
pharmacokinetics of Otamixaban, a direct factor Xa inhibitor, in healthy male subjects, 37
pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer, 1116
population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients, 1171
population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias, 59
population pharmacokinetics of oxycodone in children 6 months to 7 years old, 433
practical perspectives on the use of tipranavir in combination with other medications, 130
ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers, 567
safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin, 981
single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation, 301
single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects, 999
single-dose pharmacokinetic study of lasofoxifene in healthy volunteers and subjects with mild and moderate hepatic impairment, 29
single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers, 991
variability in renal clearance of substrates for renal transporters in Chinese subjects, 157

Pharmacologic research

what race and ethnicity measure in pharmacologic research, 401

Pharmacovigilance

national Veterans Health Administration hospitalizations for syncope compared to acute myocardial infarction, fracture, or pneumonia in community-dwelling elders: outpatient medication and comorbidity profiles, 613

Phase I study

comparison of maximum drug concentration and area under the time-concentration curve between humans and animals for oral and intravenous investigational drugs, 674

Phenotype

discordance between N-acetyltransferase 2 phenotype and genotype in a population of Hmong subjects, 802

Phosphodiesterase 4 inhibitors

investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects, 1146

Pilsicainide

population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias, 59

Plasma concentration

investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities, 235

Plasmodium

antimalarial drug therapy: the role of parasite biology and drug resistance, 1487

Platelet function analyzer (PFA-100)

antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial, 468

Pleconaril

effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe, 103

Polymorphisms

establishing functional relevance of genetic polymorphisms on pharmacokinetics, 258

P-OM3

study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters, 785

Population pharmacokinetics

development of a predictive pharmacokinetic model for a novel cyclooxygenase-2 inhibitor, 537
pharmacokinetics and safety of montelukast in children aged 3 to 6 months, 620
population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients, 1171
population pharmacokinetic and pharmacodynamic analysis of a class IC antiarrhythmic, pilsicainide, in patients with cardiac arrhythmias, 59
population pharmacokinetics of amlodipine in hypertensive children and adolescents, 905
population pharmacokinetics of oxycodone in children 6 months to 7 years old, 433

Postmenopause

effect of conjugated equine estrogens on oxidative metabolism in middle-aged and elderly postmenopausal women, 1299

Premature ejaculation

pharmacokinetics of dapoxetine, a new treatment for premature ejaculation: impact of age and effects of a high-fat meal, 1023
single- and multiple-dose pharmacokinetics of dapoxetine hydrochloride, a novel agent for the treatment of premature ejaculation, 301

Primary care

therapeutic drug monitoring of antidepressants and cytochrome P450 genotyping in general practice, 1320

Primary nocturnal enuresis

pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults, 1204

Progesterone

delay of ovulation by meloxicam in healthy cycling volunteers: a placebo-controlled, double-blind, crossover study, 925

use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults, 345

Progestin

effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function, 867

Promethazine

influence of simulated weightlessness on the intramuscular and oral pharmacokinetics of promethazine in 12 human volunteers, 1008

Protease inhibitors

time-dependent interaction between lopinavir/ritonavir and fexofenadine, 758

Protein binding

on the observed large interspecies overprediction of human clearance ("vertical allometry") of UCN-01: further support for a proposed model based on plasma protein binding, 398

Proteinuria

rosuvastatin increases a-1 microglobulin urinary excretion in patients with primary dyslipidemia, 1337

Psoralen

drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine, 768

Psoriasis

drug-drug interaction after single oral doses of the furanocoumarin methoxsalen and cyclosporine, 768

overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis, 10

QT prolongation

clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs, 498

man versus machine: is there an optimal method for QT measurements in thorough QT studies? 598

Race

race and ethnicity in the era of emerging pharmacogenomics, 405

what race and ethnicity measure in pharmacologic research, 401

Ranitidine

effect of food, an antacid, and the H_2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects, 549

Ravuconazole

effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers, 193

Receptor downregulation

drug-disease interactions: losartan effect is not downregulated by rheumatoid arthritis, 1344

Receptors

bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections, 654

Regulations

what race and ethnicity measure in pharmacologic research, 401

Renal clearance

variability in renal clearance of substrates for renal transporters in Chinese subjects, 157

Renal function

dosing of gentamicin in patients with end-stage renal disease receiving hemodialysis, 1259

effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function, 867

effect of renal function on the pharmacokinetics of palifermin, 1460

impact of disease states on the pharmacokinetics and pharmacodynamics of angiotensin-converting enzyme inhibitors, 968

pharmacokinetics of ertapenem in patients with varying degrees of renal insufficiency and in patients on hemodialysis, 1128

Renal transplant

interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients, 328

Renal transporters

variability in renal clearance of substrates for renal transporters in Chinese subjects, 157

RhCYP2B6

evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6, 1426

Rheumatoid arthritis

bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections, 654

comparability of etanercept pharmacokinetics in healthy Japanese and American subjects, 418

Ribavirin

absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects, 559

Ritonavir

practical perspectives on the use of tipranavir in combination with other medications, 130

ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers, 567

Rivaroxaban

safety, tolerability, pharmacodynamics, and pharmacokinetics of rivaroxaban—an oral, direct factor Xa inhibitor—are not affected by aspirin, 981

Rizatriptan

pharmacokinetic profile of rizatriptan 10-mg tablet and 10-mg orally disintegrating tablet administered with or without water in healthy subjects, 172

Roflumilast

investigation of a potential food effect on the pharmacokinetics of roflumilast, an oral, once-daily phosphodiesterase 4 inhibitor, in healthy subjects, 1146

Rosuvastatin

rosuvastatin increases a-1 microglobulin urinary excretion in patients with primary dyslipidemia, 1337

Rule of exponents

on the observed large interspecies overprediction of human clearance ("vertical allometry") of UCN-01: further support for a proposed model based on plasma protein binding, 398

Selective serotonin reuptake inhibitor (SSRI)

antiplatelet activity during coadministration of the selective serotonin reuptake inhibitor paroxetine and aspirin in male smokers: a randomized, placebo-controlled, double-blind trial, 468

Selegiline

tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects, 933

Serum anticholinergic activity

anticholinergic drug scale as a measure of drug-related anticholinergic burden, 1481

Single rising doses

disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia, 140

Single-nucleotide polymorphisms (SNPs)

human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity, 1356

Sirolimus

comparative study of sirolimus tablet versus oral solution for prophylaxis of acute renal allograft rejection, 76

Splice variants

human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity, 1356

St John's wort

investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach, 1370

Statins

high-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels, 812

study of the pharmacokinetic interaction between simvastatin and prescription omega-3-acid ethyl esters, 785

Steroid pharmacodynamics

reduced methylprednisolone clearance causing prolonged pharmacodynamics in a healthy subject was not associated with CYP3A5*3 allele or a change in diet composition, 515

Study design

impersistence of depression in youth: implications for drug study design, 1044

Sublingual

pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials, 179

pharmacokinetics of olanzapine after single-dose oral administration of standard tablet versus normal and sublingual administration of an orally disintegrating tablet in normal volunteers, 164

Syncope
national Veterans Health Administration hospitalizations for syncope compared to acute myocardial infarction, fracture, or pneumonia in community-dwelling elders: outpatient medication and comorbidity profiles, 613

Systematic review
impact of suppressing the renin-angiotensin system on atrial fibrillation, 21

Telbivudine
absence of food effect on the pharmacokinetics of telbivudine following oral administration in healthy subjects, 275
single-dose and multiple-dose pharmacokinetics and safety of telbivudine after oral administration in healthy Chinese subjects, 999

Tenofovir
absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects, 559

Tesaglitazar
food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, 1017

Thrombin generation time
pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies, 887

Ticlopidine
effects of ergoloid mesylates and ginkgo biloba on the pharmacokinetics of ticlopidine, 628

Tipifarnib
pharmacokinetics of tipifarnib after oral and intravenous administration in subjects with advanced cancer, 1116

Tipranavir
practical perspectives on the use of tipranavir in combination with other medications, 130

TNFR
comparability of etanercept pharmacokinetics in healthy Japanese and American subjects, 418

Tolerance
disposition kinetics and tolerance of escalating single doses of ramelteon, a high-affinity MT1 and MT2 melatonin receptor agonist indicated for treatment of insomnia, 140
pharmacokinetics, tolerability, and performance of a novel matrix transdermal delivery system of fentanyl relative to the commercially available reservoir formulation in healthy subjects, 642

Transdermal
tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects, 933

Transit absorption model
pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adults, 1204

Trimethylamine
disposition and metabolite kinetics of oral L-carnitine in humans, 1163

Trospium chloride
predictive power of an in vitro system to assess drug interactions of an antimuscarinic medication: a comparison of in vitro and in vivo drug-drug interaction studies of trospium chloride with digoxin, 776

Tumor necrosis factor
bioequivalence of liquid and reconstituted lyophilized etanercept subcutaneous injections, 654

Type 2 diabetes
food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor α/γ agonist, 1017
open-label, parallel group study investigating the effects of age and gender on the pharmacokinetics of the once-daily glucagon-like peptide-1 analogue liraglutide, 635

Tyramine pressor test
tyramine pressor sensitivity during treatment with the selegiline transdermal system 6 mg/24 h in healthy subjects, 933

UCN-01
on the observed large interspecies overprediction of human clearance ("vertical allometry") of UCN-01: further support for a proposed model based on plasma protein binding, 398

Urinary excretion
pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients, 727

Varenicline
multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy smokers, 1439
pharmacokinetics, safety, and tolerability after single and multiple oral doses of varenicline in elderly smokers, 1234
single-dose pharmacokinetics of varenicline, a selective nicotinic receptor partial agonist, in healthy smokers and nonsmokers, 991

Vertical allometry
on the observed large interspecies overprediction of human clearance ("vertical allometry") of UCN-01: further support for a proposed model based on plasma protein binding, 398

Veterans
national Veterans Health Administration hospitalizations for syncope compared to acute myocardial infarction, fracture, or pneumonia in community-dwelling elders: outpatient medication and comorbidity profiles, 613

Vincristine
pharmacokinetics and urinary excretion of vincristine sulfate liposomes injection in metastatic melanoma patients, 727

Voriconazole
investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities, 235

Warfarin
effect of exenatide on the pharmacokinetics and pharmacodynamics of warfarin in healthy Asian men, 1179
investigation of the effects of herbal medicines on warfarin response in healthy subjects: a population pharmacokinetic-pharmacodynamic modeling approach, 1370

Weightlessness
influence of simulated weightlessness on the intramuscular and oral pharmacokinetics of promethazine in 12 human volunteers, 1008

Women
use of omeprazole as a CYP3A probe drug: effect of sex and menstrual cycle phase on CYP3A activity in healthy Caucasian adults, 345

Xanthine oxidase
effect of mild and moderate hepatic impairment on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase, 88

Zolpidem
dynamics and kinetics of a modified-release formulation of zolpidem, 1469